Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trazodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 12/20 | 0.96 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.96 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.96 |
| ▸ | HTR1A | P08908 | 12/20 | 0.96 |
| ▸ | DRD2 | P14416 | 12/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.96 |
| ▸ | HPGD | P15428 | 2/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.96 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.96 |
| ▸ | HRH1 | P35367 | 2/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.96 |
| ▸ | DRD1 | P21728 | 1/20 | 0.96 |
| ▸ | DRD4 | P21917 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trazodone SCHEMBL28167 | 0.98 | HTR1A (1.00) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL29390760 | 0.98 | HTR1A (1.00) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL28226073 | 0.97 | HTR1A (0.98) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL3402550 | 0.97 | KDM4E (1.00) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL61754 | 0.97 | KDM4E (1.00) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL29575935 | 0.97 | KDM4E (1.00) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| SCHEMBL11089944 | 0.96 | HTR1A (0.98) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL27570399 | 0.93 | DRD2 (0.90) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL8741340 | 0.92 | DRD2 (0.89) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL23145121 | 0.91 | HTR1A (0.87) | HTR1ADRD2HTR2AKCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2467 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075425-A | Trazodone hydrochloride tablet and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-117100711-B | Sustained-release tablet containing trazodone hydrochloride and preparation method thereof | 江苏济茗医药有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122005477-A | Trazodone hydrochloride sustained release tablet and preparation method thereof | 南京海纳制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260108508-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| EP-4615585-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| WO-2025107056-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITION AND PREPARATION PROCESS | SANOFI MEDLEY FARMACEUTICA LTDA (BR) | 2025-05-30 | — | — | WO | claimed |
| CN-119896649-A | Preparation method of trazodone hydrochloride sustained release tablet | 山东诺明康药物研究院有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119804689-A | Method for detecting impurity of trazodone hydrochloride | 九华华源药业股份有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119280155-B | Trazodone hydrochloride liquid medicine composition for improving stability and preparation method thereof | 新基元(北京)医药科技有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119479863-A | Quality control method for trazodone hydrochloride intermediate | 沈阳盈信化工有限公司 | 2025-02-18 | — | — | CN | claimed |
| WO-2000021504-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0980247-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | Algos Pharmaceutical Corporation (US) | 2000-02-23 | — | — | EP | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1998050044-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5795895-A | Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug | ANCHORS J MICHAEL (US) | 1998-08-18 | — | — | US | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| US-4840952-A | ADMINISTERING TRAZODONE | BRISTOL-MYERS COMPANY (US) | 1989-06-20 | — | — | US | claimed |
| US-4687771-A | TRAZODONE | BRISTOL-MYERS COMPANY (US) | 1987-08-18 | — | — | US | claimed |